Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme

HealthTech approach

HealthTech approach

Advice programme

Area of interest

Showing 676 to 700 of 2570

TitleReference numberPublishedLast updated
Urinary tract infection in under 16s: diagnosis and managementNG224
Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney diseaseTA809
Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrenceTA810
PeritX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascitesHTG282
Belimumab for treating lupus nephritis (terminated appraisal)TA806
Roxadustat for treating symptomatic anaemia in chronic kidney diseaseTA807
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDsTA803
Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglyceridesTA805
ProciseDx point-of-care platform for inflammatory bowel diseaseMIB302
Fenfluramine for treating seizures associated with Dravet syndromeTA808
Setmelanotide for treating obesity caused by LEPR or POMC deficiencyHST21
Social, emotional and mental wellbeing in primary and secondary educationNG223
Cyanoacrylate glue for hernia mesh fixationMIB301
RespiraSense for continuously monitoring respiratory rateMIB299
MiraQ for assessing graft flow during coronary artery bypass graft surgeryHTG275
Teduglutide for treating short bowel syndromeTA804
Nerve graft for corneal denervationHTG629
Vertebral body tethering for idiopathic scoliosis in children and young peopleHTG628
Faricimab for treating diabetic macular oedemaTA799
Faricimab for treating wet age-related macular degenerationTA800
Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancerTA801
Cemiplimab for treating advanced cutaneous squamous cell carcinomaTA802
Depression in adults: treatment and managementNG222
Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiationTA798
Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal)TA797

Results per page

  1. 10
  2. 25
  3. 50
  4. All